http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200101160-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3584903efe1babebbd056e855a2cc2b3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a8c46bf0ed0e60df8c8533624f81231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06e14855109caac9ead3badf1cf6032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7eb0a6eb2d3c2c815b3e0caeec1a9fd |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200101160-A |
| titleOfInvention | Pharmaceutical composition for the inhibition of ocular angiogenesis comprising rivoceranib and method for inhibition of ocular angiogenesis using the same |
| abstract | The present invention relates to a pharmaceutical composition for suppressing ocular neovascularization comprising riboceranib and a method for suppressing ocular neovascularization using the same, wherein the eye drops containing riboceranib as an active ingredient include corneal neovascularization area and Since it reduces the neovascular index and reduces the number and area of blood vessels and lymphatic vessels in the corneal tissue, it can be effectively used to suppress corneal neovascularization. |
| priorityDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.